DaVita Inc. (DVA) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $209.20 (-0.26%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Oct 14, 2025 | David MacDonald | Truist Financial | $140.00 | -33.1% |
| Oct 9, 2025 | Andrew Mok | Barclays | $149.00 | -28.8% |
| Aug 8, 2025 | David MacDonald | Truist Financial | $148.00 | -29.3% |
| Feb 21, 2025 | Lisa Bedell Clive | Bernstein | $184.00 | -12.0% |
| Aug 7, 2024 | Kevin Fischbeck | Bank of America Securities | $145.00 | -30.7% |
| May 6, 2024 | Andrew Mok | Barclays | $150.00 | -28.3% |
| Oct 31, 2022 | Sarah James | Barclays | $81.00 | -61.3% |
| Aug 19, 2022 | Andrew Mok | UBS | $117.00 | -44.1% |
| Jun 28, 2022 | David MacDonald | Truist Financial | $90.00 | -57.0% |
Top Analysts Covering DVA
DVA vs Sector & Market
| Metric | DVA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.57 | 2.24 | 2.40 |
| Analyst Count | 7 | 8 | 19 |
| Target Upside | -3.1% | +11475.0% | +17.1% |
| P/E Ratio | 21.05 | 3.89 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $3.46B | $3.47B | $3.48B | 3 |
| 2026-09-30 | $3.53B | $3.54B | $3.55B | 1 |
| 2026-12-31 | $3.62B | $3.64B | $3.64B | 2 |
| 2027-03-31 | $3.41B | $3.42B | $3.42B | 1 |
| 2027-06-30 | $3.55B | $3.56B | $3.56B | 2 |
| 2027-09-30 | $3.63B | $3.64B | $3.65B | 2 |
| 2027-12-31 | $3.72B | $3.73B | $3.73B | 1 |
| 2028-12-31 | $14.64B | $14.81B | $14.98B | 3 |
| 2029-12-31 | $15.66B | $15.89B | $16.33B | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $3.61 | $3.63 | $3.63 | 3 |
| 2026-09-30 | $3.79 | $3.80 | $3.81 | 1 |
| 2026-12-31 | $4.42 | $4.44 | $4.44 | 1 |
| 2027-03-31 | $2.66 | $2.67 | $2.67 | 1 |
| 2027-06-30 | $4.11 | $4.13 | $4.14 | 1 |
| 2027-09-30 | $4.56 | $4.58 | $4.58 | 1 |
| 2027-12-31 | $4.68 | $4.70 | $4.71 | 1 |
| 2028-12-31 | $18.08 | $18.43 | $19.09 | 1 |
| 2029-12-31 | $17.77 | $18.12 | $18.76 | 1 |
Frequently Asked Questions
What is the analyst consensus for DVA?
The consensus among 7 analysts covering DaVita Inc. (DVA) is Hold with an average price target of $168.67.
What is the highest price target for DVA?
The highest price target for DVA is $184.00, set by Lisa Bedell Clive at Bernstein on 2025-02-21.
What is the lowest price target for DVA?
The lowest price target for DVA is $81.00, set by Sarah James at Barclays on 2022-10-31.
How many analysts cover DVA?
7 analysts have issued ratings for DaVita Inc. in the past 12 months.
Is DVA a buy or sell right now?
Based on 7 analyst ratings, DVA has a consensus rating of Hold (2.57/5) with a -3.1% upside to the consensus target of $168.67.
What are the earnings estimates for DVA?
Analysts estimate DVA will report EPS of $3.63 for the period ending 2026-06-30, with revenue estimated at $3.47B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.